Carboplatin, Pemetrexed, and Tislelizumab
About
Membership operator: AND
Therapies: 3
Therapies
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Pemetrexed, Tislelizumab |